Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 478 entries
Sorted by: Best Match Show Resources per page
[Evaluation of traditional Chinese medicine influence to the quality of life of patients with malignant tumors].

Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

Chen ZF, Hou YT, Hou J.
PMID: 7719098
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1994 Oct;14(10):625-6.

No abstract available.

Cite
Chen ZF, Hou YT, Hou J. [Evaluation of traditional Chinese medicine influence to the quality of life of patients with malignant tumors]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1994;14(10):625-6
Chen, Z. F., Hou, Y. T., & Hou, J. (1994). [Evaluation of traditional Chinese medicine influence to the quality of life of patients with malignant tumors]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 14(10), 625-6.
Chen, Z F, et al. "[Evaluation of traditional Chinese medicine influence to the quality of life of patients with malignant tumors]." Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine vol. 14,10 (1994): 625-6.
Chen ZF, Hou YT, Hou J. [Evaluation of traditional Chinese medicine influence to the quality of life of patients with malignant tumors]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1994 Oct;14(10):625-6. Chinese. PMID: 7719098.
Copy Download .nbib Format: NLM
[Prospects of targeted therapies in oncology and problems of their molecular determinants: clinico-pathologic relationship].

Pathologica

Sobrero A.
PMID: 14989011
Pathologica. 2003 Oct;95(5):264.

No abstract available.

Cite
Sobrero A. Le prospettive delle targeted therapies in oncologia ed i problemi dei loro determinanti molecolari: rapporto clinico-patologo. [Prospects of targeted therapies in oncology and problems of their molecular determinants: clinico-pathologic relationship]. Pathologica. 2003;95(5):264
Sobrero, A. (2003). Le prospettive delle targeted therapies in oncologia ed i problemi dei loro determinanti molecolari: rapporto clinico-patologo. [Prospects of targeted therapies in oncology and problems of their molecular determinants: clinico-pathologic relationship]. Pathologica, 95(5), 264.
Sobrero, A. "Le prospettive delle targeted therapies in oncologia ed i problemi dei loro determinanti molecolari: rapporto clinico-patologo." [Prospects of targeted therapies in oncology and problems of their molecular determinants: clinico-pathologic relationship]. Pathologica vol. 95,5 (2003): 264.
Sobrero A. Le prospettive delle targeted therapies in oncologia ed i problemi dei loro determinanti molecolari: rapporto clinico-patologo. [Prospects of targeted therapies in oncology and problems of their molecular determinants: clinico-pathologic relationship]. Pathologica. 2003 Oct;95(5):264. Italian. PMID: 14989011.
Copy Download .nbib Format: NLM
Recent developments in the chemotherapy of cancer.

Bulletin. Chicago Medical Society

REIMANN SP.
PMID: 18856838
Bull Chic Med Soc. 1948 Apr 17;50(42):716-8.

No abstract available.

Cite
REIMANN SP. Recent developments in the chemotherapy of cancer. Bull Chic Med Soc. 1948;50(42):716-8
REIMANN, S. P. (1948). Recent developments in the chemotherapy of cancer. Bulletin. Chicago Medical Society, 50(42), 716-8.
REIMANN, S P. "Recent developments in the chemotherapy of cancer." Bulletin. Chicago Medical Society vol. 50,42 (1948): 716-8.
REIMANN SP. Recent developments in the chemotherapy of cancer. Bull Chic Med Soc. 1948 Apr 17;50(42):716-8. PMID: 18856838.
Copy Download .nbib Format: NLM
Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis.

Cancer journal (Sudbury, Mass.)

Vapiwala N, Mick R, Hampshire MK, Metz JM, DeNittis AS.
PMID: 17207316
Cancer J. 2006 Nov-Dec;12(6):467-74. doi: 10.1097/00130404-200611000-00006.

PURPOSE: Complementary and alternative medicine use is prevalent in both healthy and oncologic populations. However, few data exist to quantify complementary and alternative medicine initiation specifically after cancer diagnosis. This study evaluated patients' complementary and alternative medicine usage patterns,...

Cite
Vapiwala N, Mick R, Hampshire MK, et al. Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer J. 2006;12(6):467-74doi: 10.1097/00130404-200611000-00006.
Vapiwala, N., Mick, R., Hampshire, M. K., Metz, J. M., & DeNittis, A. S. (2006). Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer journal (Sudbury, Mass.), 12(6), 467-74. https://doi.org/10.1097/00130404-200611000-00006
Vapiwala, Neha, et al. "Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis." Cancer journal (Sudbury, Mass.) vol. 12,6 (2006): 467-74. doi: https://doi.org/10.1097/00130404-200611000-00006
Vapiwala N, Mick R, Hampshire MK, Metz JM, DeNittis AS. Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer J. 2006 Nov-Dec;12(6):467-74. doi: 10.1097/00130404-200611000-00006. PMID: 17207316.
Copy Download .nbib Format: NLM
Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles.

International journal of cancer

Liu Y, Miyoshi H, Nakamura M.
PMID: 17390371
Int J Cancer. 2007 Jun 15;120(12):2527-37. doi: 10.1002/ijc.22709.

The diagnosis and treatment of cancer or tumor at the cellular level will be greatly improved with the development of techniques that enable the delivery of analyte probes and therapeutic agents into cells and cellular compartments. Organic and inorganic...

Cite
Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007;120(12):2527-37doi: 10.1002/ijc.22709.
Liu, Y., Miyoshi, H., & Nakamura, M. (2007). Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. International journal of cancer, 120(12), 2527-37. https://doi.org/10.1002/ijc.22709
Liu, Yiyao, et al. "Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles." International journal of cancer vol. 120,12 (2007): 2527-37. doi: https://doi.org/10.1002/ijc.22709
Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007 Jun 15;120(12):2527-37. doi: 10.1002/ijc.22709. PMID: 17390371.
Copy Download .nbib Format: NLM
Recent advances in cancer chemotherapy.

Bruxelles medical

HADDOW A.
PMID: 18888419
Brux Med. 1948 Oct 17;28(42):2169-75.

No abstract available.

Cite
HADDOW A. Progrès récents dans la chimiothérapie du cancer. Recent advances in cancer chemotherapy. Brux Med. 1948;28(42):2169-75
HADDOW, A. (1948). Progrès récents dans la chimiothérapie du cancer. Recent advances in cancer chemotherapy. Bruxelles medical, 28(42), 2169-75.
HADDOW, A. "Progrès récents dans la chimiothérapie du cancer." Recent advances in cancer chemotherapy. Bruxelles medical vol. 28,42 (1948): 2169-75.
HADDOW A. Progrès récents dans la chimiothérapie du cancer. Recent advances in cancer chemotherapy. Brux Med. 1948 Oct 17;28(42):2169-75. French. PMID: 18888419.
Copy Download .nbib Format: NLM
Commentary: Implications of cancer managed as a "chronic illness".

Current oncology reports

Markman M.
PMID: 21221861
Curr Oncol Rep. 2011 Apr;13(2):90-1. doi: 10.1007/s11912-010-0148-6.

In an increasing number of settings it is appropriate to consider cancer as a very serious but also a chronic disease process. This commentary discusses a number of highly clinically relevant implications of this important evolution in the management...

Cite
Markman M. Commentary: Implications of cancer managed as a "chronic illness". Curr Oncol Rep. 2011;13(2):90-1doi: 10.1007/s11912-010-0148-6.
Markman, M. (2011). Commentary: Implications of cancer managed as a "chronic illness". Current oncology reports, 13(2), 90-1. https://doi.org/10.1007/s11912-010-0148-6
Markman, Maurie. "Commentary: Implications of cancer managed as a "chronic illness"." Current oncology reports vol. 13,2 (2011): 90-1. doi: https://doi.org/10.1007/s11912-010-0148-6
Markman M. Commentary: Implications of cancer managed as a "chronic illness". Curr Oncol Rep. 2011 Apr;13(2):90-1. doi: 10.1007/s11912-010-0148-6. PMID: 21221861.
Copy Download .nbib Format: NLM
Dietary counseling: evidence in chemotherapy patients.

The journal of supportive oncology

Bauer J, Isenring E, Ferguson M.
PMID: 19149320
J Support Oncol. 2008 Nov-Dec;6(8):354-5; author reply 355.

No abstract available.

Cite
Bauer J, Isenring E, Ferguson M. Dietary counseling: evidence in chemotherapy patients. J Support Oncol. 2008;6(8):354-5; author reply 355
Bauer, J., Isenring, E., & Ferguson, M. (2008). Dietary counseling: evidence in chemotherapy patients. The journal of supportive oncology, 6(8), 354-5; author reply 355.
Bauer, Judy, et al. "Dietary counseling: evidence in chemotherapy patients." The journal of supportive oncology vol. 6,8 (2008): 354-5; author reply 355.
Bauer J, Isenring E, Ferguson M. Dietary counseling: evidence in chemotherapy patients. J Support Oncol. 2008 Nov-Dec;6(8):354-5; author reply 355. PMID: 19149320.
Copy Download .nbib Format: NLM
Drug discovery: engineering drug combinations.

Nature chemical biology

Dixon SJ, Stockwell BR.
PMID: 20404820
Nat Chem Biol. 2010 May;6(5):318-9. doi: 10.1038/nchembio.353.

No abstract available.

Cite
Dixon SJ, Stockwell BR. Drug discovery: engineering drug combinations. Nat Chem Biol. 2010;6(5):318-9doi: 10.1038/nchembio.353.
Dixon, S. J., & Stockwell, B. R. (2010). Drug discovery: engineering drug combinations. Nature chemical biology, 6(5), 318-9. https://doi.org/10.1038/nchembio.353
Dixon, Scott J, and Stockwell, Brent R. "Drug discovery: engineering drug combinations." Nature chemical biology vol. 6,5 (2010): 318-9. doi: https://doi.org/10.1038/nchembio.353
Dixon SJ, Stockwell BR. Drug discovery: engineering drug combinations. Nat Chem Biol. 2010 May;6(5):318-9. doi: 10.1038/nchembio.353. PMID: 20404820; PMCID: PMC3048766.
Copy Download .nbib Format: NLM
Theranostics for cancer therapy.

Current drug delivery

Palekar-Shanbhag P, Jog SV, Chogale MM, Gaikwad SS.
PMID: 23286214
Curr Drug Deliv. 2013 Jun;10(3):357-62. doi: 10.2174/1567201811310030013.

With over 10 million new cases per year worldwide, Cancer remains one of the most urgent health concerns and a difficult disease to treat. For an effective treatment, improved diagnostic and therapeutic techniques with minimal side-effects are required. Research...

Cite
Palekar-Shanbhag P, Jog SV, Chogale MM, et al. Theranostics for cancer therapy. Curr Drug Deliv. 2013;10(3):357-62doi: 10.2174/1567201811310030013.
Palekar-Shanbhag, P., Jog, S. V., Chogale, M. M., & Gaikwad, S. S. (2013). Theranostics for cancer therapy. Current drug delivery, 10(3), 357-62. https://doi.org/10.2174/1567201811310030013
Palekar-Shanbhag, Pradnya, et al. "Theranostics for cancer therapy." Current drug delivery vol. 10,3 (2013): 357-62. doi: https://doi.org/10.2174/1567201811310030013
Palekar-Shanbhag P, Jog SV, Chogale MM, Gaikwad SS. Theranostics for cancer therapy. Curr Drug Deliv. 2013 Jun;10(3):357-62. doi: 10.2174/1567201811310030013. PMID: 23286214.
Copy Download .nbib Format: NLM
Lifestyle behaviors and early diagnosis practices of cancer patients.

Asian Pacific journal of cancer prevention : APJCP

Yilmaz M, Sanli D, Ucgun M, Kaya NS, Tokem Y.
PMID: 23803114
Asian Pac J Cancer Prev. 2013;14(5):3269-74. doi: 10.7314/apjcp.2013.14.5.3269.

BACKGROUND: The aim was to determine the lifestyle behaviors and the practices for early diagnosis of cancer of cancer patients.MATERIALS AND METHODS: A descriptive cross-sectional design was used for this study. The sample consisted of 222 patients with a...

Cite
Yilmaz M, Sanli D, Ucgun M, et al. Lifestyle behaviors and early diagnosis practices of cancer patients. Asian Pac J Cancer Prev. 2013;14(5):3269-74doi: 10.7314/apjcp.2013.14.5.3269.
Yilmaz, M., Sanli, D., Ucgun, M., Kaya, N. S., & Tokem, Y. (2013). Lifestyle behaviors and early diagnosis practices of cancer patients. Asian Pacific journal of cancer prevention : APJCP, 14(5), 3269-74. https://doi.org/10.7314/apjcp.2013.14.5.3269
Yilmaz, Medine, et al. "Lifestyle behaviors and early diagnosis practices of cancer patients." Asian Pacific journal of cancer prevention : APJCP vol. 14,5 (2013): 3269-74. doi: https://doi.org/10.7314/apjcp.2013.14.5.3269
Yilmaz M, Sanli D, Ucgun M, Kaya NS, Tokem Y. Lifestyle behaviors and early diagnosis practices of cancer patients. Asian Pac J Cancer Prev. 2013;14(5):3269-74. doi: 10.7314/apjcp.2013.14.5.3269. PMID: 23803114.
Copy Download .nbib Format: NLM
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists.

Critical reviews in oncology/hematology

Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, Cohen A, Soria JC.
PMID: 21330149
Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79. doi: 10.1016/j.critrevonc.2011.01.009. Epub 2011 Feb 16.

Molecular targeted therapies (MTTs) have become a major component of modern management of various hematological and solid malignancies. However, some MTTs have been associated with cardiotoxicity. MTT-induced cardiovascular side effects include left ventricular systolic dysfunction, heart failure, conduction abnormalities,...

Cite
Ederhy S, Izzedine H, Massard C, et al. Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 2011;80(3):369-79doi: 10.1016/j.critrevonc.2011.01.009.
Ederhy, S., Izzedine, H., Massard, C., Dufaitre, G., Spano, J. P., Milano, G., Meuleman, C., Besse, B., Boccara, F., Kahyat, D., Cohen, A., & Soria, J. C. (2011). Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Critical reviews in oncology/hematology, 80(3), 369-79. https://doi.org/10.1016/j.critrevonc.2011.01.009
Ederhy, Stephane, et al. "Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists." Critical reviews in oncology/hematology vol. 80,3 (2011): 369-79. doi: https://doi.org/10.1016/j.critrevonc.2011.01.009
Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, Cohen A, Soria JC. Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79. doi: 10.1016/j.critrevonc.2011.01.009. Epub 2011 Feb 16. PMID: 21330149.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 478 entries